Glucagon-like peptide-1: A basis for new approaches to the management of diabetes

Drugs of Today

Volumn 35, Issue 3, 1999, Pages 159-170

  Deacon, Carolyn F ^a   Holst, Jens J ^a   Carr, Richard D ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE; GLUCOSE; INSULIN;

DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG ACTIVITY; DRUG EFFECT; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; ORAL GLUCOSE TOLERANCE TEST; REVIEW;

EID: 0032963903     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.3.533845     Document Type: Review

References (110)

1. American Diabetes Association. Medical Management of Type 2 Diabetes, 4th Ed., 1998.
2. Creutzfeldt, M. Candidate hormones of the gut. XV. Insulin-releasing factors of the gastrointestinal mucosa (Incretin). Gastroenterology 1974, 67: 748-50.
3. Creutzfeldt, W. The incretin concept today. Diabetologia 1979, 16: 75-85.
4. Holst, J.J., Ørskov, C., Nielsen, O.V., Schwartz, T.W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987, 211: 169-74.
5. Kreymann, B., Williams, G., Ghatei, M.A., Bloom, S.R. Glucagon-like peptide-1 (7-36): A physiological incretin in man. Lancet 1987, 2: 1300-4.
6. Bell, G.I., Santerre, R.F., Mullenbach, G.T. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983, 302: 716-8.
7. Ørskov, C., Holst, J.J., Knuhtsen, S., Baldissera, F.G., Poulsen, S.S., Nielsen, O.V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986, 119: 1467-75.
8. Mojsov, S., Heinrich, G., Wilson, I.B., Ravazzola, M., Orci, L., Habener, J.F. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986, 261: 11880-9.
9. Ørskov, C., Holst, J.J., Poulsen, S.S., Kirkegaard, P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987, 30: 874-81.
10. Elliott, R.M., Morgan, L.M., Tredger, J.A., Deacon, S., Wright, J., Marks, V. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns. J Endocrinol 1993, 138: 159-66.
11. Herrmann, C., Göke, R., Richter, G., Fehmann, H.C., Arnold, R., Göke, B.J. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995, 56: 117-26.
12. Ørskov, C., Wettergren, A., Holst, J.J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996, 31: 665-70.
13. Thorens, B. Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992, 89: 8641-5.
14. Ørskov, C., Holst, J.J., Nielsen, O.V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107)amide] on endocrine secretion from pig pancreas, antrum and non-antral stomach. Endocrinology 1988, 123: 2009-13.
15. Weir, G.C., Mojsov, S., Hendrick, G.K., Habener, J.F. Glucagon-like peptide 1 (7-37) actions on the endocrine pancreas. Diabetes 1989, 38: 338-42.
16. Nathan, D.M., Schreiber, E., Fogel, H., Mojsov, S., Habener. J.F. Insulinotropic action of glucagonlike peptide-1 (7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992, 15: 270-6.
17. Drucker, D.J., Philippe, J., Mojsov, S., Chick, W.L., Habener, J.F. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in rat islet cell line. Proc Natl Acad Sci USA 1987, 84: 3434-8.
18. Fehmann, H.C., Habener, J.F. Insulinotropic hormone glucagon-like peptide-1 (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinology 1992, 130: 159-66.
19. Holz, G.G., Kühtreiber, W.M., Habener, J.F. Pancreatic beta cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-36). Nature 1993, 361: 362-5.
20. Gromada, J., Dissing, S., Bokvist, K. et al. Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting βTC3-cells by enhancement of intracellular calcium mobilization. Diabetes 1995, 44: 767-74.
21. Byrne, M.M., Gliem, K., Wank, U. et al. Glucagon-like peptide 1 improves the ability of the β-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes 1998, 47: 1259-65.
22. Wang, Y., Perfetti, R., Greig, N.H. et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 1997, 99: 2883-9.
23. De Ore, K., Greig, N.H., Holloway, H.W., Wang, Y., Perfetti, R., Egan, J.M. The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test. J Gerontol A Biol Sci Med Sci 1997, 52: B245-9.
24. Egan, J.M., Zhou, J., Perfetti, R., Elahi, D. GLP-1 is a trophic factor. Dig Dis Sci 1998, 43: A220.
25. Gromada, J., Holst, J.J., Rorsman, P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide-1. Eur J Physiol 1998, 435: 583-94.
26. Heller, R.S., Kieffer, T.J., Habener, J.F. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing a-cells of the rat endocrine pancreas. Diabetes 1997, 46: 785-91.
27. 2+-induced secretion in rat α-cells by a protein kinase A-mediated mechanism. Diabetes 1997, 46: 792-800.
28. Gutniak, M., Ørskov, C., Holst, J.J., Ahrén, B., Efendic, S. Anti-diabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. New Engl J Med 1992, 326: 1316-22.
29. Ørskov, L., Holst, J.J., Møller, J. et al. GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia 1996, 39: 1227-32.
30. D'Alessio, D.A., Kahn, S.E., Leusner, C.R., Ensinck, J.W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 1994, 93: 2263-6.
31. D'Alessio, D.A., Prigeon, R.L., Ensinck, J.W. Enterai enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide 1. Diabetes 1995, 44: 1433-7.
32. Valverde, I., Morales, M., Clemente, F. et al. Glucagon-like peptide 1: A potent glycogenic hormone. FEBS Lett 1994, 349: 313-6.
33. Villanueva-Peñacarrillo, M.L., Alcántara, A.I., Clemente, F., Delgado, E., Valverde, I. Potent glycogenic effect of GLP-1 (7-36) amide in rat skeletal muscle. Diabetologia 1994, 37: 1163-6.
34. Perea, A., Vinambres, C., Clemente, F., Villanueva-Peñacarrillo, M.L., Valverde, I. GLP-1 (7-36) amide: Effects on glucose transport and metabolism in rat adipose tissue. Horm Metab Res 1997, 29: 417-21.
35. Yang, H., Egan, J.M., Wang, Y. et al. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol 1998, 275: C675-83.
36. Furnsinn, C., Ebner, K., Waldhausl, W. Failure of GLP-1 (7-36) amide to affect glycogenesis in rat skeletal muscle. Diabetologia 1995, 38: 864-7.
37. Hansen, B.F., Jensen, P., Nepper-Christensen, E., Skjolstrup, B. Effects of glucagon-like peptide-1 (7-36) amide on insulin stimulated rat skeletal muscle glucose transport. Acta Diabetol 1998, 35: 101-3.
38. Villanueva-Peñacarrillo, M.L., Delgado, E., Trapote, M.A. et al. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 1995, 146: 183-9.
39. Wettergren, A., Schjoldager, B., Mortensen, P.E., Myhre, J., Christiansen, J., Holst, J.J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993, 38: 665-73.
40. Wishart, J.M., Horowitz, M., Morris, H.A., Jones, K.L., Nauck, M.A. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 1998, 19: 1049-53.
41. Tang-Christensen, M., Larsen, P.J., Göke, R. et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996, 271: R848-56.
42. Turton, M.D., O'Shea, D., Gunn, I. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379: 69-72.
43. Flint, A., Raben, A., Astrup, A., Holst, J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101: 515-20.
44. Naslund, E., Gutniak, M., Skogar, S., Rossner, S., Hellström, P.M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998, 68: 525-30.
45. Gutzwiller, J.P., Göke, B., Drewe, J. et al. Glucagon-like peptide-1: A potent regulator of food intake in humans. Gut 1999, 44: 81-6.
46. D'Alessio, D.A., Vogel, R., Prigeon, R. et al. Elimination of the action of glucagon-like pep-tide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 1996, 97: 133-8.
47. Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., Katschinski, M. Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. Clin Invest 1998, 101: 1421-30.
48. Edwards, C.M., Todd, J.R, Mahmoudi, M. et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: Studies with the antagonist exendin 9-39. Diabetes 1999, 48: 86-93.
49. Scrocchi, L.A., Brown, T.J., MaClusky, N. et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996, 2: 1254-8.
50. Scrocchi, L.A., Marshall, B.A., Cook, S.M., Brubaker, P.L., Drucker, D.J. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 1998, 47: 632-9.
51. Vaag, A.A., Holst, J.J., Volund, A., Beck-Nielsen, H.B. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) - Evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 1996, 135: 425-32.
52. Ritzel, R., Ørskov, C., Holst, J.J., Nauck, M.A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995, 38: 720-5.
53. Nauck, M.A., Heimesaat, M.M., Ørskov, C., Holst, J.J., Ebert, R., Creutzfeldt, W. Preserved incretin activity of GLP-1 [7-36 amide] but not of synthetic human GIP in patients with type 2-diabetes mellitus. J Clin Invest 1993, 91: 301-7.
54. Nauck, M.A., Kleine, N., Ørskov, C., Holst, J.J., Willms, B., Creutzfeldt, W. Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36 amide) in type 2 diabetic patients. Diabetologia 1993, 36: 741-4.
55. Rachman, J., Gribble, F.M., Barrow, B.A., Levy, J.C., Buchanan, K.D., Turner, R.C. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 1996, 45: 1524-30.
56. Rachman, J., Barrow, B.A., Levy, J.C., Turner, R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997, 40: 205-11.
57. Willms, B., Idowu, K., Holst, J.J., Creutzfeldt, W., Nauck, M.A. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. Exp Clin Endocrinol Diabetes 1998, 106: 103-7.
58. Elahi, D., McAloon-Dyke, M., Fukagawa, N.K. et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994, 51: 63-74.
59. Willms, B., Werner, J., Holst, J.J., Ørskov, C., Creutzfeldt, W., Nauck, M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996, 81: 327-32.
60. Ahrén, B., Larsson, H., Holst, J.J. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997, 82: 473-8.
61. Qualmann, C., Nauck, M.A., Holst, J.J., Ørskov, C., Creutzfeldt, W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 1995, 32: 13-6.
62. Edwards, C.M.B., Todd, J.F., Ghatei, M.A., Bloom, S.R. Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin Sci 1998, 95: 719-24.
63. Toft-Nielsen, M., Madsbad, S., Holst, J.J. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 1998, 41: 1180-6.
64. Nauck, M.A., Holst, J.J., Willms, B. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 1997, 29: 411-6.
65. Nauck, M.A., Sauerwald, A., Ritzel, R., Holst, J.J., Schmiegel, W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998, 21: 1925-31.
66. Dupré, J., Behme, M.T., Hramiak, I.M. et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995, 44: 626-30.
67. Creutzfeldt, W.O., Kleine, N., Willms, B., Ørskov, C., Holst, J.J., Nauck, MA Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in type I diabetic patients. Diabetes Care 1996, 19: 580-6.
68. Larsen, J., Damsbo, P. GLP-1 must be present continuously in order to obtain good glycaemic control in NIDDM. Diabetes 1997, 46 (Suppl. 1): 186A.
69. Juntti-Berggren, L., Pigon, J., Karpe, F. et al. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 1996, 19: 1200-6.
70. Todd, J.R, Wilding, J.P.M., Edwards, C.M.B. Khan, F.A., Ghatei, M.A., Bloom, S.R Glucagon like peptide 1 (GLP 1): A trial of treatment in noninsulin dependent diabetes mellitus. Eur J Clin Invest 1997, 27: 533-6.
71. Nauck, M.A., Wollschläger, D., Werner, J. et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide] in patients, with NIDDM. Diabetologia 1996, 39: 1546-53.
72. Rachman, J., Turner, R.C. Drugs on the horizon for treatment of type 2 diabetes. Diabet Med 1995, 12: 467-78.
73. Nauck, M.A., Holst, J.J., Willms, B., Schmiegel, W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 1997, 105: 187-95.
74. Mentlein, R., Gallwitz, B., Schmidt, W.E. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionino and is responsible for their degradation in human serum. Eur J Biochem 1993, 214: 829-35.
75. Deacon, C.F., Johnsen, A.H., Holst, J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80: 952-7.
76. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44: 1126-31.
77. Deacon, C.F., Pridal, L., Klarskov, L., Olesen, M., Holst, J.J. Glucagon-like peptide-1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996, 271: E458-64.
78. Kieffer, T.J., McIntosh, C.H.S., Pederson, R.A. Degradation of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide 1 (tGLP-1) in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136: 3585-96.
79. Knudsen, L.B., Pridal, L. Glucagon-like peptide-1 (9-36) amide is a major metabolite of glucagon-like peptide-1 (7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996, 318: 429-35.
80. Gallwitz, B., Schmidt, W.E., Conlon, J.M., Creutzfeldt, W. Glucagon-like peptide-1(7-36) amide: Characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells. J Mol Endocrinol 1990, 5: 33-9.
81. Gefel, D., Hendrick, G.K., Mojsov, S., Habener, J., Weir, G.C. Glucagon-like peptide-1 analogs: Effects on insulin secretion and adenosine 3′,5′-monophosphate formation. Endocrinology 1990, 126: 2164-8.
82. Adelhorst, K., Hedegaard, B.B., Knudsen, L.B., Kirk, O. Structure-activity studies of glucagon-like peptide-1. J Biol Chem 1994, 269: 6275-8.
83. Wettergren, A., Wøjdemann, M., Holst, J.J. The inhibitory effect of glucagon-like peptide-1 (7-36) amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36) amide. Peptides 1998, 19: 877-82.
84. Larsen, J., Jallad, N., Damsbo, P. One-week continuous infusion of GLP-1 (7-37) improves the glycaemic control in NIDDM. Diabetes 1996, 45 (Suppl. 2): 233A.
85. Todd, J.F., Edwards, C.M.B., Ghatei, M.A., Mather, H.M., Bloom, S.R. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci 1998, 95: 325-9.
86. Heins, J., Neubert, K., Barth, A., Canizaro, P.C., Behal, F.J. Kinetic investigation of the hydrolysis of aminoacyl p-nitroanilides by dipeptidyl peptidase IV from human and pig kidney. Biochim Biophys Acta 1984, 785: 30-5.
87. Rahfeld, J., Schutkowski, M., Faust, J., Neubert, K., Barth, A., Heins, J. Extended investigation of the substrate specificity of dipeptidyl peptidase IV from pig kidney. Biol Chem Hoppe-Seyler 1991, 372: 313-8.
88. Deacon, C.F., Knudsen, L.B., Madsen, K., Wiberg, F.C., Jacobsen, O., Holst, J.J. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998, 41: 271-8.
89. Ritzel, U., Leonhardt, U., Ottleben, M. et al. A synthetic glucagon-like peptide-1 analog with improved plasma stability. J Endocrinol 1998, 159: 93-102.
90. Burcelin, R., Roland, E., Dolci, W., Carrel, V., Thorens, B. A novel gene therapy approach for the treatment of NIDDM based on encapsulated cells secreting GLP-1. Diabetes 1998, 47 (Suppl. 1): A67.
91. Burcelin, R., Dolci, W., Thorens, B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 1999, 48: 252-8.
92. Mooney, M., Kelly, C.M.N., Flatt, P.R., O'Harte, F.P.M. Aminopeptidase resistant glycated glucagon-like peptide-1 (7-36) amide shows potent insulinotropic action in vivo. Diabetologia 1998, 41 (Suppl. 1): A183.
93. Myers, S.R., Baker, J., Broderick, C., Clephane, M., Williams, V., Workman, R. LY315902: An analog of GLP-1 with enhanced activity and time action in vivo. Diabetes 1998, 47 (Suppl. 1): A193.
94. Markussen, J., Havelund, S., Kurtzhals, P. et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996, 39: 281-8.
95. Myers, S.R., Yakubu-Madus, F.E., Johnson, W.T. et al. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes 1997, 46: 637-42.
96. Pridal, L., Agerbaek, H., Christensen, L.N., Thomsen, K., Kirk, O. Absorption of glucagonlike peptide-1 can be protracted by zinc or protamine. Int J Pharm 1996, 136: 53-9.
97. Gutniak, M.K., Larsson, H., Heiber, S.J., Juneskans, O.T., Holst, J.J., Ahrén, B. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 1996, 19: 843-8.
98. Gutniak, M.K., Larsson, H., Sanders, S.W., Juneskans, O., Holst, J.J., Ährén, B. GLP-1 tablet in type 2 diabetes in fasting and post-prandial conditions. Diabetes Care 1997, 20: 1874-9.
99. Deacon, C.F., Hughes, T.E., Holst, J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs. Diabetes 1998, 47: 764-9.
100. Pederson, R.A., White, H.A., Schlenzig, D., Pauly, R.P., McIntosh, C.H., Demuth, H.U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998, 47: 1253-8.
101. Balkan, B., Kwasnik, L., Miserendino, R., Mone, M., Hughes, I.E., Li, X. Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in obese Zucker rats. Diabetologia 1997, 40 (Suppl. 1): A131.
102. Li, X., Kwasnik, L., Miserendino, R. et al. Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in insulin-resistant rats. Diabetes 1997, 46 (Suppl. 1): 237A.
103. Brand, C.L., Larsen, P.J., Nielsen, P.F., Peschke, B., Carr, R.D. Chronic administration of valine pyrrolidide, a selective inhibitor of dipeptidyl peptidase IV, improves glucose tolerance without affecting food intake in Zucker Obese Rats. Diabetes 1999, 48 (Suppl.): Abst, in press.
104. Dunning, B.E., Mone, M., Barilla, D. Inhibition of dipeptidyl peptidase IV (DPP-IV) improves oral glucose tolerance (OGT) in insulin-resistant cynomolgus monkeys. Diabetes 1998, 47 (Suppl. 1): A283.
105. Qualmann, C., Nauck, M.A., Holst, J.J. Ørskov, C., Creutzfeldt, W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using α-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995, 30: 892-6.
106. Göke, B., Fuder, H., Wieckhorst, G. et al. Voglibose (AO-128) is an efficient α-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995, 56: 493-501.
107. Seifarth, C., Bergmann, J., Holst, J.J., Ritzel, R., Schmiegel, W., Nauck, M.A. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to a-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med 1998, 15: 485-91.
108. Demuth, H.U., Heins, J. Catalytic mechanism of dipeptidyl peptidase IV. In: Dipeptidyl Peptidase IV (CD 26) in Metabolism and the Immune Response. Fleischer, B. (Ed.). R.G. Landes Biochemical Publishers: Georgetown 1995, 1-37.
109. Von Bonin, A., Huhn, J., Fleischer, E. Dipeptidyl-peptidase IV/CD26 on T cells: Analysis of an alternative T-cell activation pathway, Immunol Rev 1998, 161: 43-53.
110. Holst, J.J., Deacon, C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998, 47: 1663-70.